Get the Stockscreener App
15.68
5.87%
0.87
After Hours:
15.68
Biohaven Ltd stock is traded at $15.68, with a volume of 2.99M.
It is up +5.87% in the last 24 hours and down -31.38% over the past month.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.
See More
Previous Close:
$14.81
Open:
$14.8
24h Volume:
2.99M
Relative Volume:
1.56
Market Cap:
$1.60B
Revenue:
-
Net Income/Loss:
$-804.34M
P/E Ratio:
-1.6663
EPS:
-9.41
Net Cash Flow:
$-531.06M
1W Performance:
+0.26%
1M Performance:
-31.38%
6M Performance:
-64.95%
1Y Performance:
-55.33%
1-Day Range:
$14.37
$15.68
1-Week Range:
$14.33
$15.94
52-Week Range:
$14.33
$55.70
Biohaven Ltd Stock (BHVN) Company Profile
Name
Biohaven Ltd
Sector
Industry
Phone
203-404-0410
Address
215 CHURCH STREET, NEW HAVEN, CT
Compare BHVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BHVN
Biohaven Ltd
|
15.68 | 1.57B | 0 | -804.34M | -531.06M | -9.41 |
|
ONC
Beone Medicines Ltd Adr
|
245.93 | 25.76B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
445.43 | 114.53B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.415 | 40.54M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
84.10 | 6.44B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.81 | 65.13B | 14.09B | 4.50B | 2.96B | 39.28 |
Biohaven Ltd Stock (BHVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-19-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Sep-16-24 | Initiated | Jefferies | Buy |
| Sep-04-24 | Initiated | Bernstein | Outperform |
| Jul-24-24 | Initiated | Morgan Stanley | Overweight |
| Feb-16-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-06-24 | Initiated | UBS | Buy |
| Dec-22-23 | Initiated | H.C. Wainwright | Buy |
| Dec-08-23 | Initiated | Robert W. Baird | Outperform |
| Jan-24-23 | Initiated | SVB Securities | Outperform |
| Jan-04-23 | Initiated | JP Morgan | Overweight |
| Dec-02-22 | Initiated | BTIG Research | Buy |
| Oct-26-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Oct-12-22 | Initiated | Piper Sandler | Overweight |
| Aug-19-22 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-08-22 | Downgrade | Wedbush | Outperform → Neutral |
| May-11-22 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Oct-19-21 | Resumed | Morgan Stanley | Equal-Weight |
| Aug-10-21 | Downgrade | UBS | Buy → Neutral |
| Aug-03-21 | Reiterated | Canaccord Genuity | Buy |
| Mar-11-21 | Initiated | UBS | Buy |
| Dec-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-17-20 | Initiated | Cowen | Outperform |
| Feb-10-20 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Nov-22-19 | Initiated | Wedbush | Outperform |
| Jun-25-19 | Reiterated | Canaccord Genuity | Buy |
| May-06-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Mar-04-19 | Reiterated | Needham | Buy |
| Jul-03-18 | Reiterated | Needham | Buy |
| Jul-02-18 | Reiterated | Needham | Buy |
| Apr-05-18 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-22-18 | Reiterated | Canaccord Genuity | Buy |
| Dec-15-17 | Initiated | Canaccord Genuity | Buy |
| Oct-03-17 | Reiterated | Needham | Buy |
View All
Biohaven Ltd Stock (BHVN) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd.BHVN - PR Newswire
Jim Cramer on Biohaven Ltd. (BHVN): “I Think That This is a Buy” - Insider Monkey
Biohaven Lands Major $600 Million Deal With Oberland Capital - Finimize
How To Trade (BHVN) - news.stocktradersdaily.com
Biohaven stock hits 52-week low at $14.36 amid market challenges By Investing.com - Investing.com South Africa
Morgan Stanley maintains Biohaven stock with $63 target - Investing.com Australia
BHVN Investor Notice: Levi & Korsinsky Investigates Biohaven Ltd. for Securities Law Violations - ACCESS Newswire
Biohaven stock hits 52-week low at $14.36 amid market challenges - Investing.com Nigeria
H.C. Wainwright maintains Buy on Biohaven stock, $54 price target - Investing.com Australia
H.C. Wainwright maintains Buy on Biohaven stock, $54 price target By Investing.com - Investing.com India
Biohaven Ltd. Receives Buy Rating from Douglas Tsao Amid Promising R&D Advancements and Strategic Developments - TipRanks
Biohaven Ltd. Receives Buy Rating Amidst Promising Developments and Strategic Advancements - TipRanks
Investors in Biohaven Ltd. (BHVN) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire
Cowen reiterates Buy on Biohaven stock, maintains $75 target By Investing.com - Investing.com India
Biohaven Ltd. Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor - marketscreener.com
Cowen reiterates Buy on Biohaven stock, maintains $75 target - Investing.com
Biohaven initiates global Phase 2/3 study of BHV-8000 - TipRanks
Biohaven (BHVN) Commences Innovative Phase 2/3 Parkinson's Drug Trial | BHVN Stock News - GuruFocus
TD Cowen on Biohaven Pharmaceutical Holding (BHVN): 'This Pipeline Is Impressive', 'Buy BHVN' - StreetInsider
Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor - PR Newswire
Biohaven’s BHV-1510 shows promise in early cancer trial By Investing.com - Investing.com South Africa
Biohaven’s BHV-1400 shows promise in IgA nephropathy treatment By Investing.com - Investing.com South Africa
Optimistic Buy Rating for Biohaven Ltd. Amid Promising Pipeline and Regulatory Challenges - TipRanks
Biohaven Ltd.: Promising Pipeline and Undervaluation Justify Buy Rating - TipRanks
Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class - The Malaysian Reserve
Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors - The Malaysian Reserve
Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Trea - StreetInsider
Biohaven Ltd. (BHVN)’s BHV-1400 Cuts Disease Antibody by 81% in IgA Nephropathy - Insider Monkey
Biohaven’s BHV-1400 shows promise in IgA nephropathy treatment - Investing.com Australia
Biohaven (BHVN) Advances Innovative Drug Trials for Immune Diseases | BHVN Stock News - GuruFocus
Biohaven (BHVN) Reports Promising Phase 1 Results for Cancer Tre - GuruFocus
Biohaven Pharma (BHVN) Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day - StreetInsider
Biohaven says anti-cancer agent cut tumor size with Regeneron’s Libtayo in Phase 1 trial - Seeking Alpha
Lost Money on Biohaven Ltd. (BHVN)? Contact Levi & Korsinsky About Investigation - ACCESS Newswire
Biohaven Ltd. Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and Fgfr3 Antibody Drug Conjugates Incorporating Novel Topoix Payload with Potential to Treat A Wide Variety of Tumors - marketscreener.com
Biohaven’s BHV-1510 shows promise in early cancer trial - Investing.com Australia
Biohaven (BHVN) Reports Promising Early Results in Oncology Prog - GuruFocus
Biohaven Presents Oncology Program Updates And Preliminary Clinical Data - marketscreener.com
Biohaven Pharma (BHVN) Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates - StreetInsider
Breakthrough: Biohaven's New Cancer Drug Achieves Perfect Response Rate in First 6 Patients Treated - Stock Titan
Inozyme Pharma and Biohaven Pharmaceuticals Announce Leadership Changes Amid Industry Restructuring - geneonline.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biohaven Ltd. - GlobeNewswire Inc.
(BHVN) Long Term Investment Analysis - news.stocktradersdaily.com
Biohaven’s SWOT analysis: stock faces regulatory hurdles amid pipeline potential - Investing.com Nigeria
Biohaven (NYSE:BHVN) Downgraded by Royal Bank of Canada to Sector Perform - Defense World
Biohaven (BHVN) Sees Downgraded Rating and Lowered Price Target - GuruFocus
RBC Downgrades Biohaven Amid Market Valuation Concerns - Finimize
Biohaven Has Lots Of Shots, Too Many Risks, RBC Says - marketscreener.com
Biohaven Ltd Stock (BHVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.48%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):